XML 25 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information (Detail) (USD $)
 3 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2014
Second Right to Develop Collaboration [Member]
Mar. 31, 2014
Servier [Member]
Mar. 31, 2013
Servier [Member]
Dec. 31, 2013
Servier [Member]
Mar. 31, 2014
Servier [Member]
Second Right to Develop Collaboration [Member]
Mar. 31, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Jan. 31, 2013
Gilead [Member]
Molecule
Mar. 31, 2014
Gilead [Member]
Mar. 31, 2013
Gilead [Member]
Dec. 31, 2013
Gilead [Member]
Jan. 31, 2013
Gilead [Member]
Expired Option Agreement [Member]
Molecule
Jan. 31, 2013
Gilead [Member]
License Agreement Terms [Member]
Molecule
Jan. 31, 2013
Gilead [Member]
Option Agreement [Member]
Program
Jan. 31, 2013
Gilead [Member]
Minimum [Member]
Jan. 31, 2013
Gilead [Member]
Maximum [Member]
Oct. 31, 2010
Boehringer [Member]
Molecule
Payments
Mar. 31, 2014
Boehringer [Member]
Mar. 31, 2013
Boehringer [Member]
Dec. 31, 2013
Boehringer [Member]
Jan. 31, 2011
Boehringer [Member]
Series D-2 Convertible Preferred Stock [Member]
Oct. 31, 2010
Pfizer [Member]
Molecule
Mar. 31, 2014
Pfizer [Member]
Program
Mar. 31, 2013
Pfizer [Member]
Dec. 31, 2013
Pfizer [Member]
Mar. 31, 2014
Green Cross [Member]
Mar. 31, 2013
Green Cross [Member]
Dec. 31, 2013
Green Cross [Member]
License And Collaboration Agreements [Line Items]                                                            
Collaboration agreement date       November 2011     September 2012       January 2013                 October 2010         October 2010     June 2010    
Non-refundable upfront payment       $ 20,000,000     $ 20,000,000     $ 7,500,000                 $ 15,000,000         $ 5,000,000     $ 5,000,000 $ 5,500,000    
Additional license grant fees 15,000,000   15,000,000 30,000,000     65,000,000     7,500,000                                        
Clinical milestone payments 5,000,000   5,000,000 47,000,000     98,000,000                       41,000,000           17,000,000     2,500,000    
Regulatory milestone payments       140,000,000     300,000,000                       89,000,000                      
Sales milestone payments       208,000,000     630,000,000                       83,000,000           195,000,000          
Expected period of development       27 months     29 months           21 months                                  
Recognized revenue under agreement       200,000 2,300,000   7,400,000 2,200,000     2,200,000 1,700,000               3,100,000 2,300,000       200,000 1,300,000   1,400,000 25,000.0  
Deferred revenue       600,000   900,000 22,100,000   9,400,000                     11,000,000   12,800,000           625,000   650,000
Clinical milestone payments under agreement             5,000,000                                              
Offset to research and development costs under collaboration arrangement 82,000                                                          
Expected development period 82 months                                                          
Review period 30 days                                                          
Deferred revenue included in current liabilities 19,665,764 20,267,323         9,500,000   8,600,000   2,400,000   3,600,000             7,000,000   7,000,000     0   7,291 100,000   100,000
Deferred revenue included in long-term liabilities 17,160,723 7,135,687         12,600,000   800,000                     4,000,000   5,800,000           525,000   550,000
Commercialization of molecules                   4       1 1 2     10         2            
Clinical milestone payments under agreement                                 20,000,000 25,000,000                        
Additional clinical, regulatory and sales milestone payments                                 240,000,000 250,000,000                        
Number of annual maintenance payments received                                     3                      
Preferred Stock purchased                                             10,000,000              
Research obligation completion date                                       2015-09         2014-01          
Period of agreement                                                 3 years          
DART program                                                 1          
Term of the agreement                                                       2020-06    
Additional clinical, regulatory and sales milestone payments $ 1,300,000